| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11370755 | ACADIA PHARMS INC | Compositions of trofinetide |
Aug, 2040
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9212204 | ACADIA PHARMS INC | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
Jan, 2032
(7 years from now) | |
Daybue is owned by Acadia Pharms Inc.
Daybue contains Trofinetide.
Daybue has a total of 2 drug patents out of which 0 drug patents have expired.
Daybue was authorised for market use on 10 March, 2023.
Daybue is available in solution;oral dosage forms.
Daybue can be used as treatment of rett syndrome or a symptom thereof.
Drug patent challenges can be filed against Daybue from 11 March, 2027.
The generics of Daybue are possible to be released after 03 August, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Treatment: Treatment of rett syndrome or a symptom thereof
Dosage: SOLUTION;ORAL
More Information on Dosage
DAYBUE family patents
